Get the Stockscreener App
1.95
2.01%
-0.04
Pre-market:
2.05
0.10
+5.13%
In 8 Bio Inc stock is traded at $1.95, with a volume of 93,004.
It is down -2.01% in the last 24 hours and down -10.14% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$1.99
Open:
$1.97
24h Volume:
93,004
Relative Volume:
1.37
Market Cap:
$8.85M
Revenue:
-
Net Income/Loss:
$-31.88M
P/E Ratio:
-2.60
EPS:
-0.75
Net Cash Flow:
$-25.20M
1W Performance:
-8.88%
1M Performance:
-10.14%
6M Performance:
-61.54%
1Y Performance:
-76.80%
1-Day Range:
$1.92
$2.02
1-Week Range:
$1.92
$2.15
52-Week Range:
$1.91
$12.53
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.95 | 9.03M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Up 85.8% in October - Defense World
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site - GlobeNewswire Inc.
Cabaletta Bio, Inc. Updates on Rese-cel Clinical Trials and FDA Alignment - TradingView
Tourmaline Bio Announces Board and Executive Resignations Following Merger - TradingView
Why Nuvation Bio Inc. stock is a must watch in 2025Trade Entry Report & Long-Term Safe Investment Ideas - fcp.pa.gov.br
Cabaletta Bio, Inc. Presents Clinical Data and Updates at ACR Convergence 2025 - TradingView
INmune Bio (NASDAQ: INMB) schedules results call for 4:30 PM ET on Oct 30 - Stock Titan
Q32 Bio Inc Completes Enrollment in SIGNAL-AA Phase 2a Trial - TradingView
[8-K] bioAffinity Technologies, Inc. Reports Material Event | BIAF SEC FilingForm 8-K - Stock Titan
PALI annual meeting: directors elected, auditor ratified, split approved - Stock Titan
Stop Loss: Why Nuvation Bio Inc. stock is popular among millennials2025 Sector Review & Breakout Confirmation Alerts - Trung tâm Dự báo KTTV quốc gia
Samsung to invest $110 mn in Grail to bring early-cancer test to Asia - KED Global
Climb Bio Publishes Long-Term Data on Budoprutug - TradingView
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025 - Stock Titan
CLYM reports budoprutug Phase 1b follow-up: 3-year control in 4 pts - Stock Titan
Palisade Bio Provides Corporate and Compliance Update - TradingView
PALI back in Nasdaq bid-price compliance; 133.0M shares out - Stock Titan
[8-K] Inmune Bio, Inc. Reports Material Event | INMB SEC FilingForm 8-K - Stock Titan
ANVS prices $6.0M offering; adds pre-funded and agent warrants - Stock Titan
[8-K] – Inmune Bio, Inc. (INMB) (CIK 0001711754) - Stock Titan
Inmune Bio Inc Announces Participation in Dermatologic Panel - TradingView
Oct 22 CEO Panel: INmune Bio's CORDStrom for RDEB — David Moss at Maxim Growth Summit in NYC - Stock Titan
US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership - Reuters
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 - GlobeNewswire
Is Mustang Bio Inc. stock ready for a breakoutJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - newser.com
OrbiMed Funds Buy into Adicet Bio Offering; Ownership Diluted to 9.6% - Stock Titan
Layoff Tracker: Ferring To Cut 500 Employees as Part of Business Model Shift - BioSpace
TELA insider award: 11,925 RSUs; option for 17,550 shares at $1.48 - Stock Titan
Korro Bio, Inc. (KRRO) Stock Price, News, Quote & History - Yahoo
TELA (TELA) Initial Form 3 — Director Records Zero Holdings - Stock Titan
Palisade Bio, Inc. Cancels Special Meeting of Stockholders - TradingView
[8-K] PALISADE BIO, INC. Reports Material Event | PALI SEC FilingForm 8-K - Stock Titan
[SCHEDULE 13G] PALISADE BIO, INC. SEC Filing - Stock Titan
Perceptive Discloses 9.99% Stake in Palisade Bio (12.24M Shares) - Stock Titan
PALI grants 7,665,800 RSUs to Chief Medical Officer; vesting over 2 years - Stock Titan
PALI Form 4: 9.18M RSUs granted to director/officer - Stock Titan
Bio, semiconductor, content firms to reboot Korea’s IPO market - KED Global
Commodore Capital and principals disclose 9.9% holding in PALI - Stock Titan
Deep Track discloses 6.43M pre-funded warrants, holds 9.99% of PALI - Stock Titan
Nuvation Bio Inc. (NUVB): A Bull Case Theory - Insider Monkey
PlayStation sale round-up for North America October 8, 2025 - TrueTrophies
Brokerages Set Gossamer Bio, Inc. (NASDAQ:GOSS) Price Target at $8.50 - Defense World
[8-K] Adicet Bio, Inc. Reports Material Event | ACET SEC FilingForm 8-K - Stock Titan
Morning Market Movers: SPRB, LXEO, BMEA, Seeing Big Swings - RTTNews
70.0M shares: Adicet Bio Prices $80M Registered Direct Offering - Stock Titan
Adicet's ADI-001 yields immune-reset signals; Phase 2 targeted Q2 2026 - Stock Titan
Morning Market Movers: DBVT, CLPT, DWTX, Seeing Big Swings - RTTNews
$138M Raised: Palisade Bio Closes Upsized Offering to Fund Phase 2 PALI-2108 - Stock Titan
Biopsy Devices Market Poised for Steady Growth by 2032, Fueled by Innovation and Increasing Surgical Procedures | DelveInsight - The Globe and Mail
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Mucopolysaccharidosis III Pipeline 2025: Pioneering Clinical - openPR.com
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):